Raffi F, et al. Switching from an abacavir (ABC)/lamivudine (3TC)-based regimen to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF): Cardiovascular disease risk profile analysis from a randomized controlled study in virologically-suppressed adults. AIDS 2018.
Samen het tij keren, in de zorg en als individu
dec 2024 | Gynaecologische oncologie